{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:33:18Z","timestamp":1793845998210,"version":"4.6.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>We explored the effectiveness of continuous glucose monitoring for 1 year on glycated A1c reduction in adults with type 1 diabetes mellitus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included type 1 diabetes mellitus adults who were either new continuous glucose monitoring users (<jats:italic>N<\/jats:italic> = 155) or non-users who were under standard care (<jats:italic>N<\/jats:italic> = 384). Glycated A1c was measured at baseline and 3, 6, 9, and 12 months. Individuals with (<jats:italic>N<\/jats:italic> = 155) or without continuous glucose monitoring use (<jats:italic>N<\/jats:italic> = 310) were matched 1:2 by propensity score. We used the linear mixed models to identify the quantitative reduction in repeated measures of glycated A1c.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The change in glycated A1c from baseline to 12 months was \u22120.5% \u00b1 1.0% for the continuous glucose monitoring user group (<jats:italic>N<\/jats:italic> = 155, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and \u22120.01% \u00b1 1.0% for the non-user group (<jats:italic>N<\/jats:italic> = 310, <jats:italic>P<\/jats:italic> = 0.816), with a significant difference between the two groups (<jats:italic>P<\/jats:italic> = 0.003). Changes in glycated A1c were significant at 3, 6, 9, and 12 months compared with those at baseline in patients using continuous glucose monitoring (<jats:italic>P<\/jats:italic> &amp;lt; 0.001), and the changes differed significantly between the groups (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). A linear mixed model showed an adjusted treatment group difference in mean reduction in glycated A1c of \u22120.11% (95% confidence interval, \u22120.16 to \u22120.06) each three months. In the continuous glucose monitoring user group, those who achieved more than 70% of time in range significantly increased from 3 months (37.4%) to 12 months (48.2%) (<jats:italic>P<\/jats:italic> &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this longitudinal study of type 1 diabetes mellitus adults, the use of continuous glucose monitoring for 1 year showed a significant reduction in glycated A1c in real-world practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1165471","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T05:04:35Z","timestamp":1684127075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of continuous glucose monitoring on glycemic control and its derived metrics in type 1 diabetes: a longitudinal study"],"prefix":"10.3389","volume":"14","author":[{"given":"So Hyun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seohyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Man","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yeon","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1089\/dia.2017.0029","article-title":"Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters","volume":"19","author":"Wright","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0820-z","article-title":"Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes","volume":"50","author":"Kilpatrick","year":"2007","journal-title":"Diabetologia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0619-1","article-title":"A view beyond HbA1c: role of continuous glucose monitoring. diabetes therapy : research, treatment and education of diabetes and related disorders","volume":"10","author":"Chehregosha","year":"2019","journal-title":"Diabetes ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19975","article-title":"Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial","volume":"317","author":"Beck","year":"2017","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31535-5","article-title":"Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial","volume":"388","author":"Bolinder","year":"2016","journal-title":"Lancet (London England)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S2213-8587(16)30193-0","article-title":"Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial","volume":"4","author":"van Beers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0306","article-title":"Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE in-home study","volume":"17","author":"Weiss","year":"2015","journal-title":"Diabetes Technol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. a consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0156","article-title":"Clinical practice guidelines for diabetes mellitus of the Korean diabetes association","volume":"45","author":"Hur","year":"2021","journal-title":"Diabetes Metab J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0257","article-title":"Time in range from continuous glucose monitoring: a novel metric for glycemic control","volume":"44","author":"Yoo","year":"2020","journal-title":"Diabetes Metab J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","article-title":"6. glycemic targets: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311854","article-title":"Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study","volume":"66","author":"Sinn","year":"2017","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00125-010-1918-2","article-title":"HbA1 (c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-derived average glucose (ADAG) study","volume":"54","author":"Borg","year":"2011","journal-title":"Diabetologia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11892-016-0808-5","article-title":"Update on clinical utility of continuous glucose monitoring in type 1 diabetes","volume":"16","author":"Haviland","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01589-3","article-title":"Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"58","author":"Dicembrini","year":"2021","journal-title":"Acta diabetologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1459","article-title":"Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta-analysis of randomized controlled trials","volume":"43","author":"Maiorino","year":"2020","journal-title":"Diabetes Care"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.6530","article-title":"Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes","volume":"325","author":"Karter","year":"2021","journal-title":"Jama"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02619.x","article-title":"Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"65","author":"Giugliano","year":"2011","journal-title":"Int J Clin Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14065","article-title":"Associations between HbA(1c) and continuous glucose monitoring-derived glycaemic variables","volume":"36","author":"Hirsch","year":"2019","journal-title":"Diabetic Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-Range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac034","article-title":"Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring","volume":"107","author":"Yapanis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19976","article-title":"Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial","volume":"317","author":"Lind","year":"2017","journal-title":"Jama"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0146","article-title":"Measures of glycemic variability in type 1 diabetes and the effect of real-time continuous glucose monitoring","volume":"18","author":"El-Laboudi","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30297-6","article-title":"Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial","volume":"391","author":"Heinemann","year":"2018","journal-title":"Lancet (London England)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0108","article-title":"The effect of continuous glucose monitoring in well-controlled type 1 diabetes","volume":"32","author":"Beck","year":"2009","journal-title":"Diabetes Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2337\/dc10-1989","article-title":"Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes","volume":"34","author":"Battelino","year":"2011","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1468","article-title":"Sustained intensive treatment and long-term effects on HbA(1c) reduction (SILVER study) by CGM in people with type 1 diabetes treated with MDI","volume":"44","author":"Lind","year":"2021","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1165471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T05:04:38Z","timestamp":1684127078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1165471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":32,"alternative-id":["10.3389\/fendo.2023.1165471"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1165471","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"article-number":"1165471"}}